TRISTEL plc
("Tristel" or the
"Company")
Notice of Interim
Results
Investor presentations
Tristel plc (AIM: TSTL), the manufacturer of
infection prevention products, announces that its interim results
for the six months to 31 December 2023 will be announced on Monday
26 February 2024.
Analyst briefing
A briefing open to analysts will
take place in London on Monday 26 February 2024
at 9.30am. To register and for more details please
contact Walbrook PR on tristel@walbrookpr.com
Investor
presentations
Paul Swinney, CEO, and Liz Dixon, CFO, will
present the Company's results in two separate events open to all
investors. The same presentation will be given at both events which
are being held at different times to offer convenient options for
those wishing to attend.
Two presentations will take place on
Monday 26 February 2024 at the following times,
the first will be held online via the Investor Meet Company
platform and the second will be held in-person in the City of
London, full details below:
1. Investor Meet
Company online presentation
Tristel management will provide a
live online presentation relating to the interim
results via Investor Meet Company at 11:30 GMT. The
presentation is open to all existing and potential shareholders.
Questions can be submitted pre-event via your Investor Meet Company
dashboard up until 9am the day before the meeting or at any time
during the live presentation.
Investors can sign up to Investor
Meet Company for free and add to meet Tristel
plc via:
https://www.investormeetcompany.com/tristel-plc/register-investor
2. In-person investor
presentation
Tristel management will provide an
in-person presentation relating to the
Company's interim results at 16:30 GMT, which is open to all
existing and potential shareholders. The
Company welcomes investors to 85 Gresham Street, London, EC2V
7NQ from 16.15
for a 16.30 start and will be followed by refreshments.
If you would like to attend, please
contact Walbrook PR on 020 7933 8780 or
email tristel@walbrookpr.com.
The results presentation will be
made available on the Company's website on the day of
results www.investors.tristel.com
For further
information please contact:
|
Tristel plc
|
Tel: 01638 721
500
|
|
Paul Swinney, Chief Executive
Officer
|
www.investors.tristel.com
|
|
Liz Dixon, Chief Financial
Officer
|
|
|
|
|
|
Walbrook PR Ltd
|
Tel: 020 7933 8780
or tristel@walbrookpr.com
|
|
Paul McManus
|
Mob: 07980
541 893
|
|
Charlotte
Edgar
|
Mob: 07884 664 686
|
|
|
|
|
Cavendish Capital Markets Ltd
|
Tel: 020 7220
0500
|
|
Geoff Nash / Charlie Beeson
(Corporate Finance)
|
|
|
Sunila de Silva (ECM)
|
|
|
|
| |
About Tristel
plc
Tristel plc is a global infection
prevention company focussed on the manufacture and supply of
products using its unique proprietary chlorine dioxide
(ClO2) chemistry. The Company is a market leader
in manual decontamination of medical devices, supplying
hospitals under the Tristel brand, and under the
Cache brand provides
products for sporicidal surface disinfection, a more sustainable
alternative to commonly used pre-wetted plastic wipes.
Tristel's head office and manufacturing
facility is located in Snailwell, near Cambridge, and operates
globally employing approximately 250 people across 14 subsidiaries
selling into 40 countries. The Company targets annual revenue
growth of between 10% and 15% and an EBITDA margin of at least 25%
(targets to be updated in February 2024) and the business is
profitable, with no debt and has a progressive dividend
policy.
The Company has been listed on the London Stock
Exchange's AIM market since 2005 (AIM: TSTL).
For more information about Tristel's product
range please visit: https://tristel.com